SCHEMBL19342129

SCHEMBL19342129

CCC(Sc1nc2c(cnn2-c2ccccc2)c(=O)[nH]1)C(=O)OC

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 4/20 1.00
SMN1; SMN2 Q16637 1/20 0.85
TSHR P16473 2/20 0.82
LMNA P02545 1/20 0.82
MEN1 O00255 4/20 0.77
KMT2A Q03164 4/20 0.77
ATM Q13315 1/20 0.77
HTT P42858 1/20 0.70
TP53 P04637 2/20 0.66
L3MBTL1 Q9Y468 1/20 0.66
CYP1A2 P05177 2/20 0.64
CYP3A4 P08684 2/20 0.64
CYP2C9 P11712 2/20 0.64
CYP2C19 P33261 1/20 0.64
DAPK3 O43293 2/20 0.63
PIM1 P11309 2/20 0.63
PIM3 Q86V86 2/20 0.63
HSD17B10 Q99714 1/20 0.58
PTGS2 P35354 1/20 0.56
HPGD P15428 1/20 0.54

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL19342082 0.90 TSHR (0.82) ALDH1A1SMN1; SMN2TSHRLMNAMEN1
SCHEMBL19342115 0.89 DAPK3 (0.81) ALDH1A1SMN1; SMN2TSHRLMNAMEN1
SCHEMBL19342105 0.88 DAPK3 (0.79) ALDH1A1SMN1; SMN2TSHRLMNAMEN1
SCHEMBL19342123 0.87 MEN1 (1.00) ALDH1A1SMN1; SMN2TSHRLMNAMEN1
SCHEMBL22042834 0.84 MEN1 (0.83) ALDH1A1SMN1; SMN2TSHRLMNAMEN1
SCHEMBL22042822 0.82 SMN1; SMN2 (0.78) ALDH1A1SMN1; SMN2TSHRLMNAMEN1
SCHEMBL22042854 0.80 MEN1 (0.80) ALDH1A1SMN1; SMN2TSHRMEN1KMT2A
SCHEMBL22071798 0.80 L3MBTL1 (1.00) ALDH1A1SMN1; SMN2TSHRLMNAMEN1
SCHEMBL19342086 0.80 KMT2A (0.81) ALDH1A1SMN1; SMN2TSHRMEN1KMT2A
SCHEMBL19327574 0.79 DAPK3 (0.80) ALDH1A1SMN1; SMN2TSHRMEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20210155627-A1 KINASE INHIBITORS AND RELATED METHODS OF USE UTI LIMITED PARTNERSHIP (CA) 2021-05-27 US disclosed
US-10934291-B2 Kinase inhibitors and related methods of use DUKE UNIVERSITY (US) 2021-03-02 US disclosed
US-20170260191-A1 KINASE INHIBITORS AND RELATED METHODS OF USE DUKE UNIVERSITY 2017-09-14 US disclosed
US-20170260191-A1 KINASE INHIBITORS AND RELATED METHODS OF USE DUKE UNIVERSITY 2017-09-14 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10934291-B2 Kinase inhibitors and related methods of use DAPK2, DAPK1, DAPK3 ALDH1A1 4082/4885SMN1; SMN2 3495/4885TSHR 3374/4885
US-20170260191-A1 KINASE INHIBITORS AND RELATED METHODS OF USE DAPK2, DAPK1, DAPK3 ALDH1A1 4082/4885SMN1; SMN2 3495/4885TSHR 3374/4885
US-20210155627-A1 KINASE INHIBITORS AND RELATED METHODS OF USE DAPK2, DAPK1, DAPK3 ALDH1A1 4082/4885SMN1; SMN2 3495/4885TSHR 3374/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.